246 related articles for article (PubMed ID: 28511567)
1. Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?
Patel AB; Wilds BW; Deininger MW
Expert Rev Hematol; 2017 Jul; 10(7):659-674. PubMed ID: 28511567
[TBL] [Abstract][Full Text] [Related]
2. Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.
Akard LP; Bixby D
Leuk Lymphoma; 2016 May; 57(5):1002-14. PubMed ID: 26726949
[TBL] [Abstract][Full Text] [Related]
3. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.
Benjamini O; Kantarjian H; Rios MB; Jabbour E; O'Brien S; Jain P; Cardenas-Turanzas M; Faderl S; Garcia-Manero G; Ravandi F; Borthakur G; Quintas-Cardama A; Cortes J
Leuk Lymphoma; 2014 Dec; 55(12):2879-86. PubMed ID: 23927391
[TBL] [Abstract][Full Text] [Related]
4. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations.
Haznedaroglu IC
Expert Opin Pharmacother; 2013 Oct; 14(15):2005-10. PubMed ID: 23984805
[TBL] [Abstract][Full Text] [Related]
5. Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.
Mathisen MS; Kantarjian HM; Cortes J; Jabbour EJ
Blood Rev; 2014 Sep; 28(5):179-87. PubMed ID: 24984571
[TBL] [Abstract][Full Text] [Related]
6. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
7. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Al-Kali A; Kantarjian H; Shan J; Bassett R; Quintás-Cardama A; Borthakur G; Jabbour E; Verstovsek S; O'Brien S; Cortes J
Cancer; 2011 Jan; 117(2):327-35. PubMed ID: 20845478
[TBL] [Abstract][Full Text] [Related]
8. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
9. Cessation of tyrosine kinase inhibitors in patients with chronic-phase chronic myelogenous leukemia following durable complete molecular response: a single center facing the dilemma.
Iliakis T; Papadopoulou V; Diamantopoulos PT; Panayiotidis P; Zervakis K; Giannakopoulou N; Tilimidos G; Angelopoulou M; Siakantaris MP; Pangalis G; Mantzourani M; Variami E; Viniou NA
Anticancer Res; 2013 Aug; 33(8):3509-14. PubMed ID: 23898127
[TBL] [Abstract][Full Text] [Related]
10. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
Sasaki K; Kantarjian HM; Jain P; Jabbour EJ; Ravandi F; Konopleva M; Borthakur G; Takahashi K; Pemmaraju N; Daver N; Pierce SA; O'Brien SM; Cortes JE
Cancer; 2016 Jan; 122(2):238-48. PubMed ID: 26479889
[TBL] [Abstract][Full Text] [Related]
11. First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.
Saglio G; Jabbour E
Leuk Lymphoma; 2018 Jul; 59(7):1523-1538. PubMed ID: 28972424
[TBL] [Abstract][Full Text] [Related]
12. Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.
DeAngelo DJ; Chen L; Guerin A; Styles A; Giguere-Duval P; Wu EQ
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):245-51. PubMed ID: 24393622
[TBL] [Abstract][Full Text] [Related]
13. What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia?
Harrington P; Radia D; de Lavallade H
Expert Rev Hematol; 2020 Mar; 13(3):213-222. PubMed ID: 31952452
[No Abstract] [Full Text] [Related]
14. [A study to determine the safety and efficacy of imatinib mesylate in patients with chronic phase of chronic myeloid leukemia after interferon therapy failure. Four year follow-up].
Hołowiecki J; Konopka L; Bober G; Giebel S; Ceglarek B; Kos K; Stella-Hołowiecka B; Kruzel T; Kopera M; Bartkowska-Chrobok A; Pszenna E; Sikorska A; Pieńikowska-Grela B
Pol Arch Med Wewn; 2006 Jun; 115(6):535-44. PubMed ID: 17263225
[TBL] [Abstract][Full Text] [Related]
15. A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.
Webster JA; Robinson TM; Blackford AL; Warlick E; Ferguson A; Borrello I; Zahurak M; Jones RJ; Smith BD
Leuk Res; 2021 Dec; 111():106737. PubMed ID: 34768161
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
Firwana B; Sonbol MB; Diab M; Raza S; Hasan R; Yousef I; Zarzour A; Garipalli A; Doll D; Murad MH; Al-Kali A
Int J Cancer; 2016 Mar; 138(6):1545-53. PubMed ID: 26455714
[TBL] [Abstract][Full Text] [Related]
17. Complexity of chronic-phase CML management after failing a second-generation TKI.
El Fakih R; Chaudhri N; Alfraih F; Rausch CR; Naqvi K; Jabbour E
Leuk Lymphoma; 2020 Apr; 61(4):776-787. PubMed ID: 31739705
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data.
Gambacorti-Passerini C; Chen C; Davis C; Sen GP; Guyan C; Hehlmann R; Michallet M; Paquette R; Goldberg SL
Eur J Haematol; 2021 Jan; 106(1):82-89. PubMed ID: 32989776
[TBL] [Abstract][Full Text] [Related]
20. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]